Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune (Nasdaq: ALT) reported first quarter 2026 results and a business update. Cash, cash equivalents and short-term investments were $332 million on March 31, 2026 and $535 million on April 30, 2026, reflecting recent equity financings.
Pemvidutide received FDA Breakthrough Therapy Designation for MASH, with the global PERFORMA Phase 3 trial expected to start in the second half of 2026. Topline RECLAIM Phase 2 AUD data are expected in the third quarter of 2026, and RESTORE Phase 2 ALD enrollment is expected to complete in the same period.
First quarter 2026 R&D expenses were $16.2 million, G&A were $8.1 million, interest income was $2.9 million, and net loss was $22.6 million, or $0.18 per share.
Altimmune (Nasdaq: ALT) will present new pemvidutide data from the Phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis (MASH) at the EASL Congress 2026 in Barcelona, May 27-30.
Presentations include 48-week efficacy and safety results, 24-week fibrosis regression by digital pathology, non-invasive test responses, and cardiovascular risk factor data. The 48-week abstract was selected for Best of EASL 2026.
Altimmune (Nasdaq: ALT) will report first quarter 2026 financial results on Wednesday, May 13, 2026 and will host a conference call at 8:30 a.m. ET the same day. The call will be webcast live on the company's Investor Relations website and a replay will be available for up to three months.
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide for serious liver diseases; management will provide a business update during the call.
Altimmune (Nasdaq: ALT) closed an oversubscribed underwritten public offering that generated approximately $225 million of gross proceeds at closing on April 27, 2026. The offering included 64,250,000 common shares and accompanying common stock warrants, plus up to 10,750,000 pre-funded warrants and accompanying warrants.
The combined offering price was $3.00 per share-and-warrant (pre-funded combos at $2.999). Proceeds are intended to fund the planned Phase 3 MASH trial and provide cash runway through the anticipated 52-week data readout; the company expects to initiate Phase 3 in H2 2026.
Altimmune (Nasdaq: ALT) priced an oversubscribed underwritten offering expected to raise approximately $225 million in gross proceeds. The deal comprises 64,250,000 common shares and accompanying warrants, plus up to 10,750,000 pre-funded warrants and accompanying warrants.
Combined offering prices are $3.00 per share-plus-warrant and $2.999 per pre-funded-warrant-plus-warrant; warrants exercise at $3.00, expire on the fifth anniversary or 45 days after a Phase 3 pemvidutide MASH successful readout. Proceeds are intended to fund the Phase 3 MASH trial, working capital and general corporate purposes.
Altimmune (Nasdaq: ALT) commenced a proposed underwritten public offering of common stock, pre-funded warrants and accompanying common stock warrants on April 22, 2026. The offering is subject to market conditions and may not be completed. Altimmune intends to use net proceeds to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH) and for working capital and general corporate purposes. Leerink Partners and Barclays are joint bookrunners; Titan Partners is co-bookrunner. Securities will be offered under previously effective Form S-3 shelf registration statements and a preliminary prospectus supplement will be filed with the SEC.
Altimmune (Nasdaq: ALT) reported Q4 and full‑year 2025 results and provided clinical and corporate updates on March 5, 2026. Key items: $274M cash and short‑term investments at Dec 31, 2025 (up ~107% YoY), a $75M registered direct offering in Jan 2026, FDA Breakthrough Therapy Designation for pemvidutide in MASH, and planned Phase 3 MASH initiation in 2026.
Topline RECLAIM Phase 2 AUD data expected Q3 2026; RESTORE ALD Phase 2 enrollment ongoing. 2025 R&D was $66.4M, G&A $28.1M, and net loss reported as $88.1M for the year.
Altimmune (Nasdaq: ALT) said management will attend four investor conferences March 9–12, 2026, offering one-on-one meetings and several fireside chats.
Webcasts of fireside chats at Leerink, Citizens and Barclays will be available via the company Events page; registered investors may request meetings through bank sales contacts.
Altimmune (Nasdaq: ALT) will report fourth quarter and full year 2025 financial results on March 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a business update.
According to Altimmune, the live webcast will be available on the company's Investor Relations website, dial-in registration is required for participants, and a replay will be accessible for up to three months.
Altimmune (Nasdaq: ALT) closed a registered direct offering raising approximately $75 million gross through sale of 17,045,454 shares of common stock (or pre-funded warrants) on Jan 29, 2026. Proceeds will fund the planned Phase 3 pemvidutide trial for MASH, plus working capital and general corporate purposes. The pre-funded warrants are exercisable immediately at $0.001 per share. Titan Partners acted as sole placement agent; the offering was made from an effective shelf registration declared effective Dec 5, 2025.